Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

Flare Therapeutics to Present Immune Profiling Data From Urothelial Cancer Patients Treated with Anti-PD1 Therapy at AACR 2024 Annual Meeting

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association For Cancer Research (AACR) Annual Meeting 2024